Eli Lilly and Company
Inhibiting the transient receptor potential A1 ion channel
Last updated:
Abstract:
The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
Status:
Grant
Type:
Utility
Filling date:
28 Dec 2018
Issue date:
31 Dec 2019